Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm
- 27 June 2009
- journal article
- research article
- Published by Springer Nature in Journal of Pharmacokinetics and Pharmacodynamics
- Vol. 36 (4) , 317-339
- https://doi.org/10.1007/s10928-009-9124-x
Abstract
Pharmacogenetics is now widely investigated and health institutions acknowledge its place in clinical pharmacokinetics. Our objective is to assess through a simulation study, the impact of design on the statistical performances of three different tests used for analysis of pharmacogenetic information with nonlinear mixed effects models: (i) an ANOVA to test the relationship between the empirical Bayes estimates of the model parameter of interest and the genetic covariate, (ii) a global Wald test to assess whether estimates for the gene effect are significant, and (iii) a likelihood ratio test (LRT) between the model with and without the genetic covariate. We use the stochastic EM algorithm (SAEM) implemented in MONOLIX 2.1 software. The simulation setting is inspired from a real pharmacokinetic study. We investigate four designs with N the number of subjects and n the number of samples per subject: (i) N = 40/n = 4, similar to the original study, (ii) N = 80/n = 2 sorted in 4 groups, a design optimized using the PFIM software, (iii) a combined design, N = 20/n = 4 plus N = 80 with only a trough concentration and (iv) N = 200/n = 4, to approach asymptotic conditions. We find that the ANOVA has a correct type I error estimate regardless of design, however the sparser design was optimized. The type I error of the Wald test and LRT are moderatly inflated in the designs far from the asymptotic (<10%). For each design, the corrected power is analogous for the three tests. Among the three designs with a total of 160 observations, the design N = 80/n = 2 optimized with PFIM provides both the lowest standard error on the effect coefficients and the best power for the Wald test and the LRT while a high shrinkage decreases the power of the ANOVA. In conclusion, a correction method should be used for model-based tests in pharmacogenetic studies with reduced sample size and/or sparse sampling and, for the same amount of samples, some designs have better power than others.Keywords
This publication has 36 references indexed in Scilit:
- Benefit of therapeutic drug monitoring of protease inhibitors in HIV-infected patients depends on PI used in HAART regimen - ANRS 111 trialFundamental & Clinical Pharmacology, 2009
- Influence of pharmacogenetics on indinavir disposition and short-term response in HIV patients initiating HAARTEuropean Journal of Clinical Pharmacology, 2009
- Comparison of Model-Based Tests and Selection Strategies to Detect Genetic Polymorphisms Influencing Pharmacokinetic ParametersJournal of Biopharmaceutical Statistics, 2008
- Extension of the SAEM algorithm for nonlinear mixed models with 2 levels of random effectsBiostatistics, 2008
- Effect of CYP2C19 polymorphism on nelfinavir to M8 biotransformation in HIV patientsBritish Journal of Clinical Pharmacology, 2008
- The SAEM algorithm for group comparison tests in longitudinal data analysis based on non‐linear mixed‐effects modelStatistics in Medicine, 2007
- Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV‐infected patientsBritish Journal of Clinical Pharmacology, 2007
- Design in nonlinear mixed effects models: Optimization using the Fedorov–Wynn algorithm and power of the Wald test for binary covariatesStatistics in Medicine, 2007
- Impact of modelling intra‐subject variability on tests based on non‐linear mixed‐effects models in cross‐over pharmacokinetic trials with application to the interaction of tenofovir on atazanavir in HIV patientsStatistics in Medicine, 2006
- Evaluation of hypothesis testing for comparing two populations using NONMEM analysisJournal of Pharmacokinetics and Biopharmaceutics, 1992